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TAU is a microtubule-associated protein that under pathological conditions such as
Alzheimer’s disease (AD) forms insoluble, filamentous aggregates. When 20 years after
TAU’s discovery the first TAU transgenic mouse models were established, one declared
goal that was achieved was the modeling of authentic TAU aggregate formation in the
form of neurofibrillary tangles. However, as we review here, it has become increasingly
clear thatTAU causes damage much before these filamentous aggregates develop. In fact,
because TAU is a scaffolding protein, increased levels and an altered subcellular localiza-
tion (due to an increased insolubility and impaired clearance) result in the interaction of
TAU with cellular proteins with which it would otherwise either not interact or do so to a
lesser degree, thereby impairing their physiological functions. We specifically discuss the
non-axonal localization of TAU, the role phosphorylation has in TAU toxicity and how TAU
impairs mitochondrial functions. A major emphasis is on what we have learned from the
four availableTAU knock-out models in mice, and the knock-out of theTAU/MAP2 homolog
PTL-1 in worms. It has been proposed that in human pathological conditions such as AD,
a rare toxic TAU species exists which needs to be specifically removed to abrogate TAU’s
toxicity and restore neuronal functions. However, what is toxic in one context may not be
in another, and simply reducing, but not fully abolishing TAU levels may be sufficient to
abrogate TAU toxicity.
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INTRODUCTION
TAU belongs to the family of microtubule-associated proteins
(MAPs) (Dehmelt and Halpain, 2005). MAPs act in concert
with heterodimers of α- and β-tubulin to assemble microtubules.
They were named according to the three major size classes of
polypeptides: MAP1 (>250 kDa), MAP2 (∼200 kDa), and TAU
(50–70 kDa) (Dehmelt and Halpain, 2005; Halpain and Dehmelt,
2006). MAP2 and TAU are expressed together in most neurons,
where they localize to separate subcellular compartments. MAP2
is largely found in dendrites, whereas TAU is concentrated in axons
(Matus, 1990). TAU has also been found in astrocytes and oligo-
dendrocytes, although, under physiological conditions, its levels
are relatively low (Tashiro et al., 1997). In concert with actin and
intermediate filaments, microtubules establish and maintain the
overall internal architecture of the cytoplasm and thereby com-
prise a major determinant of overall cell shape (Allen et al.,
1985; Vale et al., 1985; Nangaku et al., 1994; Trinczek et al.,
1999). Besides interacting with cytoskeletal proteins, MAPs also
interact with proteins that have a range of cellular functions, sug-
gesting that TAU is a scaffolding protein (Brandt and Leschik,
2004). Scaffolding proteins are defined as being able to bind at
least two signaling proteins, and localizing signaling molecules
and transduction pathways to defined cellular locations – for
instance the cell body, dendrites or the axon, and to regulate
signaling (Shaw and Filbert, 2009). We discuss here that TAU
has these properties and that the toxicity of TAU is, at least
in parts, because this scaffolding function is either altered or
lost.
When TAU was discovered in 1975 (Weingarten et al., 1975), the
subsequent years focused mainly on its tissue distribution and role
in microtubule assembly and stabilization. The focus shifted radi-
cally when TAU was identified in Alzheimer’s disease (AD) brains
in a highly phosphorylated form as the filamentous core of the
neurofibrillary tangles (NFTs) (Grundke-Iqbal et al., 1986; Goed-
ert et al., 1988). Histopathologically, AD is also characterized by
β-amyloid (Aβ)-containing plaques, reduced synaptic density, and
neuronal loss in selected brain areas. Interestingly, although NFTs
were initially correlated with dementia (Arriagada et al., 1992), it
was also found that firstly, CA1 hippocampal neurons can survive
with NFTs for about 20 years, and secondly that NFTs may not
be obligatory for the death of CA1 hippocampal neurons in AD
(Morsch et al., 1999). This does not, however, preclude that NFT-
carrying neurons are functionally impaired. For a discussion of the
role of NFTs in neurodegeneration, see e.g., Castillo-Carranza et al.
(2013). In addition to AD, neurofibrillary lesions are also abundant
in other neurodegenerative diseases such as Pick’s disease, progres-
sive supranuclear palsy (PSP), corticobasal degeneration (CBD),
argyrophilic grain disease (AGD), and frontotemporal dementia
with Parkinsonism linked to chromosome 17 (FTDP-17), where
they occur in the absence of overt Aβ deposition. When we, for the
first time, expressed human TAU in transgenic mice, we were able
to reproduce key aspects of the human TAU pathology (Götz et al.,
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1995). Specifically, overexpression of human TAU resulted in the
accumulation of hyperphosphorylated forms of TAU not only in
the axonal compartment, but also in the somatodendritic domain.
NFT formation, however, was not achieved by this approach. It
was the identification of pathogenic mutations in familial cases
of frontotemporal lobar degeneration (FTLD) in the MAPT gene
encoding TAU (Clark et al., 1998; Hutton et al., 1998; Poorkaj et al.,
1998) that enabled us and others to express FTLD mutant forms of
TAU in mice. Thus, we not only reproduced NFT formation, but in
addition placed TAU downstream of Aβ in a patho-cascade – a cen-
tral concept in the field (Götz et al., 2001a,b). Despite this, TAU
is not simply an innocent bystander in Aβ toxicity, as discussed
below. In fact, the dendritic localization of the “axonal” protein
TAU not only has a role in physiological postsynaptic scaffold-
ing, but it is also crucial for mediating Aβ’s toxicity (Ittner et al.,
2010). This and complementary studies in cell culture have put
forth the argument that reducing or completely abolishing TAU
expression might be beneficial in combating neurodegeneration in
AD (Rapoport et al., 2002; Roberson et al., 2007; Ittner and Götz,
2011; Morris et al., 2011b).
In the following, we discuss what we have learned about TAU’s
toxicity in models that over-express TAU and as a consequence,
develop TAU aggregates and NFTs. As this article is part of a series
that investigates TAU toxicity from various angles, we will restrict
our discussion to selected aspects and will specifically discuss
TAU’s role in non-axonal compartments, how it affects mito-
chondrial functions and what we have learned from invertebrate
models. We draw the conclusion that TAU is a scaffolding protein
and that its mislocalization disrupts cellular processes because it
traps proteins with which it would otherwise not interact (or do so
to a lesser degree) and thereby prevents them from executing their
physiological functions. This does not rule out that the aggregates
themselves are toxic, although the current experimental models
do not allow for a dissociation of the effects elicited by the aggre-
gates from those elicited by soluble TAU species. In the second
part we discuss what we have learned from TAU knock-out mod-
els in mice and what the knockout of the worm homolog of TAU,
PTL-1, has contributed to an understanding of TAU function. In
the final paragraph, we attempt to integrate findings in both TAU
over-expressing and knock-out models.
WHAT CAUSES TOXICITY WHEN THERE IS TOO MUCH TAU?
In an attempt to model TAU pathology in mice, the first TAU
transgenic mouse model was established 20 years after TAU’s dis-
covery by over-expressing the longest of the six major human
TAU isoforms, hTau40 (Götz et al., 1995) (For comparison, in the
adult mouse brain, there are only three TAU isoforms expressed.).
These htau40 transgenic mice reproduce aspects of the human
pathology, such as somatodendritic localization and hyperphos-
phorylation of TAU. Subsequently, stronger promoters were used
to drive expression, resulting in more pronounced phenotypes
(Ishihara et al., 1999; Spittaels et al., 1999; Probst et al., 2000).
Despite the formation of TAU aggregates and an age-dependent
decrease in TAU solubility, NFTs did not form until a very old
age in these mice (Ishihara et al., 2001). However, signs of Waller-
ian degeneration including axonal breakdown and segmentation
of myelin into ellipsoids were observed. Furthermore, neurogenic
muscle atrophy, with groups of small angular muscle fibers, was
present in the hind leg musculature of the transgenic mice (Probst
et al., 2000). Another characteristic was the presence of large num-
bers of axonal spheroids in brainstem and spinal cord (Ishihara
et al., 1999; Spittaels et al., 1999; Probst et al., 2000). Similar
swellings have also been described in transgenic mice with Aβ
plaque formation, and in the human AD brain (Stokin et al., 2005).
Following the identification of pathogenic mutations in MAPT
in FTDP-17, TAU filament formation was achieved in neurons and
glia, both by constitutive and doxycycline-regulated expression of
mutant human forms of TAU (Götz and Götz, 2009). The first
published mouse strain with pronounced NFT formation, JNPL3,
expressed P301L mutant human TAU under the control of the
murine PrP promoter. This resulted in abnormal TAU filament
formation in neurons as well as astrocytes and oligodendrocytes,
with NFTs being present in brain and spinal cord (Lewis et al.,
2000). Neuronal loss was found in the spinal cord, as evidenced by
a twofold reduction in the numbers of motor neurons. Further-
more, the mice developed severe motor disturbances by 10 months
of age. We established a second model with NFT formation, pR5
mice, by expressing the same P301L mutation, but using a different
human TAU isoform and the neuron-specific mThy1.2 promoter
for transgene expression (Götz et al., 2001a). While a motor phe-
notype was absent, reference memory was impaired and the mice
displayed an increased exploratory behavior (Pennanen et al.,
2006). Furthermore, owing to a pronounced expression of the
transgene in the amygdala, the mice showed an accelerated extinc-
tion in the conditioned taste aversion paradigm (Pennanen et al.,
2004). When experimental diabetes was induced in pR5 mice, this
caused an earlier-onset and increased formation of NFTs, indicat-
ing that diabetes can accelerate the onset and increase the severity
of disease in individuals with a predisposition to develop a tauopa-
thy (Ke et al., 2009). To determine whether NFTs are integral
components of the neurotoxic cascade in AD or whether they
represent a protective neuronal response, transgenic mice were
generated which allowed for the regulation of P301L TAU expres-
sion by adding doxycycline to the drinking water (Santacruz et al.,
2005). Because the system resulted in a 15-fold over-expression,
this caused a progressive formation of NFTs, a remarkable neu-
ronal loss (70% in the CA1 region), gross atrophy of the brain,
and behavioral impairment. Turning the system “off” caused a
reduction of TAU levels to 2.5-fold over-expression. Nonetheless,
this was sufficient to cause a recovery of memory functions and
stabilization of neuron numbers, while NFTs continued to accu-
mulate. These data imply that NFTs per se are not sufficient to
cause cognitive decline or neuronal death (Santacruz et al., 2005).
While the pR5 mice display memory impairment as a major
clinical feature of AD, another feature, Parkinsonism, that char-
acterizes a significant subset of FTLD cases, has been modeled
in K369I mutant TAU transgenic K3 mice. We established this
strain based on the identification of the K369I mutation of TAU
in a single patient with Pick’s disease (Neumann et al., 2001),
and reproduced the distinct characteristics of Pick’s pathology in
mice (Ittner et al., 2008). Memory functions were impaired as
shown in the novel object recognition test. Owing to a unique
expression pattern of the transgene that extends to the Substantia
Nigra pars compacta (SNpc), the K3 mice also model early onset
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Parkinsonism, i.e., resting tremor, bradykinesia, postural instabil-
ity, and gait anomalies. They show an increased cataleptic response
to haloperidol and an early, but not late, response to l-DOPA,
indicating that the dopaminergic system is impaired. We found a
selectively impaired axonal transport of distinct cargos including
mitochondria and tyrosine hydroxylase (TH)-containing vesicles.
An important finding is that at the molecular level, this transport
impairment is the result of the accumulation of hyperphospho-
rylated TAU in the cell body, where it traps the adapter protein
and a component of the kinesin motor machinery, JIP1, thereby
preventing this molecule from executing its physiological func-
tion in the axon (Ittner et al., 2008). A pathological interaction
between TAU and JIP1 was further revealed in AD and not con-
trol brain (Ittner et al., 2009). It seems therefore that for TAU
to be able to exert toxicity, the subcellular compartments it is
aberrantly targeted to are crucial, as this determines with which
proteins it pathologically interacts and which cellular functions it
impairs. In this process, phosphorylation of TAU has a critical role
as reviewed by us recently (Götz et al., 2010). That phosphory-
lation of TAU is critical in toxicity is also evident from studies
in protein phosphatase 2A (PP2A) dominant negative mutant
strains. More specifically, to address the role of the TAU phos-
phatase PP2A in mice with a pre-existing TAU pathology, we
crossed the PP2A dominant negative mutant strain Dom5 with
pR5 mice that express P301L mutant TAU and found that this
exacerbated the TAU pathology of pR5 mice significantly. The
double-transgenic mice showed sevenfold increased numbers of
hippocampal neurons that specifically phosphorylated the patho-
logical Ser422 epitope of TAU (Deters et al., 2009). The mice
showed eightfold increased numbers of NFTs compared with pR5
mice, in agreement with our previous finding that NFT forma-
tion is correlated with and preceded by phosphorylation of TAU
at the Ser422 epitope (Götz et al., 2001b). We further used the
Dom5 mice to show that a small compound, sodium selenate,
improves TAU-dependent impairment and neurodegeneration in
a PP2A-dependent manner (van Eersel et al., 2010). Together this
demonstrates that phosphorylated forms of TAU have a critical
role in TAU toxicity.
The tauopathies PSP and CBD are characterized by substan-
tial glial TAU pathology. Aspects of this pathology have been
reproduced by expressing G272V mutant TAU under the con-
trol of the PrP promoter that resulted in high transgene expres-
sion in a subset of both neurons and oligodendrocytes. Electron
microscopy established that TAU filament formation was asso-
ciated with hyperphosphorylation of TAU. Thioflavin S-positive
fibrillary inclusions were identified in oligodendrocytes and motor
neurons (Götz et al., 2001c), the clinical phenotype of these mice
however was subtle. In contrast, when human wild-type TAU was
overexpressed in neurons and glial cells under the control of the
mouse Tα1 α-tubulin promoter, a glial pathology was obtained
that closely resembled the astrocytic plaques of CBD and the coiled
bodies of both CBD and PSP (Higuchi et al., 2002). A significant
age-related neuronal loss was only found at 18 months of age,
whereas oligodendrocytes were lost already at 6 months. The same
team employed the 2′,3′-cyclic nucleotide 3′-phosphodiesterase
promoter to express human P301L TAU exclusively in oligo-
dendrocytes (Higuchi et al., 2005). Interestingly, the structural
disruption of myelin and axons preceded the emergence of TAU
inclusions in oligodendrocytes; also, impaired axonal transport
was found to precede the motor deficits in these mice (Higuchi
et al., 2005). Together, these studies highlight a role for glial TAU
in disease.
While most studies on TAU use the mouse as a model organism,
several wild-type and mutant human TAU transgenic models have
been established in the nematode C. elegans (Kraemer et al., 2003;
Miyasaka et al., 2005; Brandt et al., 2009; Fatouros et al., 2012).
Some of these models have been reviewed in detail (Ewald and Li,
2010) and are not discussed here.
In the following, we will discuss two important aspects of
TAU toxicity, one is the impairment of mitochondrial functions,
and the second the role TAU has in the dendrite. Mitochondrial
dysfunction has long been associated with the pathophysiology
of AD (Blass and Gibson, 1991). The morphology of a cellu-
lar mitochondrial network is maintained by reciprocal rounds
of fission and fusion, a process termed mitochondrial dynamics.
Elevated fusion produces elongated, interconnected mitochon-
dria, while enhanced fission results in mitochondrial fragmen-
tation. Mitochondrial dynamics cannot be discussed in isolation,
as fission (biogenesis), fusion, bioenergetics, motility/transport,
and turnover by mitophagy are highly inter-dependent processes
(Chen and Chan, 2009). How TAU impairs the fission and fusion
of mitochondria, has been reviewed by us recently (Duboff et al.,
2013), following the finding of a role of TAU in altering mito-
chondrial dynamics. Specifically we had found that in human TAU
transgenic mice and flies, F-actin is increased, which disrupts the
physical association of mitochondria and the fission protein DRP1,
leading to mitochondrial elongation (Duboff et al., 2012). The
resulting neurotoxicity can be rescued either by reducing mito-
chondrial fusion, or by enhancing fission, or by reversing actin
stabilization.
Earlier, we had analyzed P301L TAU transgenic pR5 mice by
MALDI TOF/TOF mass-spectrometric analysis, which revealed
a deregulation of mainly metabolism-related proteins including
mitochondrial respiratory chain complex components such as
the complex V component ATP synthase D chain, antioxidant
enzymes, and synaptic proteins (David et al., 2005). A subsequent
functional analysis demonstrated a mitochondrial dysfunction in
pR5 mice together with a reduced NADH-ubiquinone oxidore-
ductase activity and, with age, impaired mitochondrial respiration
and ATP synthesis. Mitochondrial dysfunction was associated with
higher levels of reactive oxygen species (ROS) in aged transgenic
mice and an up-regulation of antioxidant enzymes. When complex
V levels were analyzed in human FTDP-17 patient brains carrying
the P301L TAU mutation, a significant decrease in complex V levels
was found in all P301L human brain samples compared with con-
trols, underscoring the validity of the proteomics findings in mice
for the human disease (David et al., 2005). A serial analysis of gene
expression (SAGE) of the same mouse strain looking specifically
at the amygdala also revealed deregulated mitochondrial genes (Ke
et al., 2012a).
Mitochondrial functions are also impaired by Aβ and as there
are many findings that support the notion of a cross-talk of Aβ and
TAU in affecting mitochondrial functions (Eckert et al., 2010),
it was reasonable to cross pR5 mice with Aβ plaque-forming
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APPswPS2N141I double-transgenic APP152 mice to generate triple-
transgenic (tripleAD) mice that combine both pathologies in one
model (Grueninger et al., 2010). Quantitative isobaric-tag label-
ing (iTRAQ) followed by mass spectrometry revealed a massive
deregulation of 24 proteins, of which one third were mitochondr-
ial proteins mainly related to complexes I and IV of the oxidative
phosphorylation system (OXPHOS). When mitochondrial func-
tions were addressed, this revealed that deregulation of complex
I is TAU-dependent, whereas deregulation of complex IV is Aβ-
dependent, both at the protein and activity level (Rhein et al.,
2009). In addition, synergistic effects of Aβ and TAU were evident
in the tripleAD mice establishing a molecular link between Aβ and
TAU protein in AD pathology in vivo (Rhein et al., 2009). In the
P301L TAU transgenic pR5 mice, a transcriptomic analysis further
revealed an up-regulation of glyoxalase I that detoxifies dicarbonyl
compounds and thereby reduces the formation of advanced gly-
cation end (AGE) products (Chen et al., 2004). Co-staining with a
phospho-TAU antibody suggested glyoxalase I up-regulation as an
early defense mechanism to combat elevated levels of aggregated
TAU. To understand which processes are disrupted by Aβ in the
presence of TAU aggregates, we applied comparative proteomics
to Aβ-treated P301L TAU-expressing neuroblastoma cells and the
amygdala of P301L TAU transgenic pR5 mice that had been stereo-
taxically injected with Aβ preparations. We found that a significant
fraction of proteins that were altered in both systems belonged
to the same functional categories, i.e., proteins involved in the
stress-response associated with protein folding (David et al., 2006).
Among the deregulated proteins was valosin containing protein
(VCP), an essential component of the ER-associated degradation
(ERAD) process, whereas members of the peroxiredoxin family
were down-regulated. Together this indicates that TAU and Aβ
exert both separate and synergistic toxic effects that are mediated
by mitochondria and the stress-related unfolded protein response.
The amyloid cascade hypothesis in a patho-cascade places Aβ
upstream of TAU (Hardy, 2006). This concept has been proven
in P301L mutant TAU transgenic mice that develop an increased
number of NFTs, either by crossing them with Aβ plaque-forming
transgenic mice (Lewis et al., 2001), or by stereotaxically inject-
ing Aβ into their brains (Götz et al., 2001b). That Aβ toxicity is
dependent on TAU has first been shown in vitro because primary
neuronal cultures derived from TAU knock-out mice were resis-
tant to the toxic effects of Aβ (Rapoport et al., 2002). This finding
was subsequently reproduced in vivo, by crossing Aβ plaque-
forming mice that are characterized by premature mortality, high
susceptibility to experimentally induced excitotoxic seizures and
memory deficits, onto a TAU knock-out background (Roberson
et al., 2007). Mechanistically, this protection appeared to be con-
ferred by a reduced susceptibility to excitotoxicity when TAU was
either absent or when its levels were reduced (Roberson et al.,
2007). Excitotoxicity is the over-activation of NMDA receptors
(NMDARs) that results in neuronal damage and death because of
increased calcium influx and nitric oxide (NO) activation (Palop
and Mucke, 2009). By using another APP plaque-forming mouse
strain and a different TAU knock-out strain, we were able to repro-
duce the TAU-dependent protection from Aβ-induced premature
mortality and memory deficits, and determined that this pro-
tection is conferred by a reduced susceptibility to excitotoxicity
(Ittner et al., 2010). Likewise, overexpression of a truncated form
of TAU (∆Tau) that lacks the microtubule-binding region MBR
also rescued the phenotype of the Aβ plaque-forming mice (Ittner
et al., 2010). In a more recent model, tau pathology was shown to
develop independent of Aβ (Winton et al., 2011). This was shown
by finding no differences in TAU lesion formation when crossing
3xTg-AD mice that co-express mutant forms of APP, presenilin
and TAU and hence develop a plaque and TAU pathology, with a
mouse strain that lacks the enzyme BACE1 required for Aβ gener-
ation. However, it has to be considered that the TAU pathology in
the 3xTg-AD mice develops very late and is modest compared with
that of other widely used TAU transgenic mouse models (Oddo
et al., 2003a,b).
What is the mechanistic explanation for this protection con-
ferred by reduction of TAU? We next showed that TAU is also
present in the dendrite (although in low quantities compared with
the axon), where it is critically involved in postsynaptic NMDAR
downstream signaling by localizing the SRC kinase FYN to the den-
drite. FYN phosphorylates the NMDAR that then recruits the post-
synaptic scaffolding protein PSD-95 to form a complex. Because
levels of postsynaptic FYN are massively reduced in TAU-deficient
or ∆Tau-expressing mice, this results in uncoupling of NMDARs
from excitotoxic signaling and abrogation of Aβ-mediated toxic-
ity (Ittner et al., 2010; Ittner and Götz, 2011). A subsequent study
found that Aβ causes a range of deleterious effects on TAU includ-
ing its localization to dendrites (Zempel et al., 2010). Aβ, Fyn, and
TAU therefore seem to orchestrate neuronal damage (Haass and
Mandelkow, 2010; Ittner et al., 2010; Roberson et al., 2011). An
essential role for FYN in this process is supported by the fact that
the pathology of Aβ plaque-forming mice is enhanced when FYN
is overexpressed and ameliorated when FYN is absent (Chin et al.,
2004, 2005).
TAU interacts with FYN at least in two ways. Firstly, although
TAU is mainly phosphorylated on serine and threonine residues, it
also contains three tyrosine residues. Tyr18 is phosphorylated by
FYN, and the phosphorylated motif interacts with FYN via FYN’s
SH2 domain. Secondly, TAU contains seven PXXP motifs located
in the amino-terminus (all of which are retained in the ∆Tau
construct). Of these, the seventh proline-rich RTPPKSP motif has
been shown to be crucial for the interaction with the SH3 domain
of FYN and other SRC non-receptor tyrosine kinases (Lee et al.,
1998; Bhaskar et al., 2010; Ittner et al., 2010). Interestingly, this
motif is also critical in the interaction of TAU with the phosphatase
PP2A that exists as a heterotrimeric holoenzyme complex. It has
been shown recently that the PP2A regulatory subunit Bα binds
to and dephosphorylates TAU, and thereby regulates microtubule
stability (Sontag et al., 2012). When FYN is bound to the (seventh)
proline-rich RTPPKSP motif that is conserved in both TAU and
MAP2, this inhibits the interaction of PP2A/Bα with either TAU
or MAP2. The corresponding synthetic RTPPKSP peptide, but
not the phosphorylated RpTPPKSP version, competes with TAU
and MAP2 for binding to PP2A/Bα. This finding is remarkable
because the down-regulation of PP2A/Bα and the deregulation of
FYN/TAU interactions have been linked to enhanced TAU phos-
phorylation in AD (Sontag et al., 2012). MAP2 is mainly a dendritic
protein as mentioned above. Why MAP2 cannot compensate for
the absence of TAU in TAU knock-out mice and target FYN to the
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dendritic spine is not understood, especially as both MAP2 and
TAU have been shown to efficiently bind to FYN.
WHAT ARE THE EFFECTS OF REDUCED TAU LEVELS?
As reviewed in detail recently, a series of TAU knock-out mouse
strains have been generated to gain insight into the physiological
functions of TAU, and while initially reported to be overtly nor-
mal, behavioral changes and motor deficits were identified at least
for some of these strains (Ke et al., 2012b).
Work in primary neuronal cultures laid the foundation: when
TAU was down-regulated using antisense oligonucleotides, this
caused a reduced neuronal outgrowth (Caceres and Kosik, 1990).
However, the first TAU knock-out mice established by Harada
et al. (1994) a few years later were surprisingly normal, with no
evidence of either an altered axonal elongation or any macro-
scopic change. In a compensatory mechanism for the absence of
TAU, MAP1A was up-regulated, and the axon caliber was altered
to what is typically found in dendrites. Primary neuronal cul-
tures established from these TAU knock-out mice did not display
a reduced neuronal outgrowth phenotype, contrasting with ear-
lier observations of neurons in which TAU levels had been reduced
using antisense approaches (Harada et al., 1994; Takei et al., 2000).
Nonetheless, the absence of TAU is not without consequences as
the hypoplasticity of the commissural tract and the disorganiza-
tion of the neuronal layering found in MAP1B knock-out mice
(Takei et al., 1997) is exacerbated by cross-breeding these mice
with TAU knock-out mice (Takei et al., 2000).
In 2001, two additional TAU knock-out lines became avail-
able. The first was established by Dawson et al. (2001), who used
the same strategy as Harada and colleagues by replacing the first
coding exon of TAU with a neomycin selection cassette, thereby
abrogating TAU expression. The second“knock-in”strain was gen-
erated by Tucker et al. (2001), who inserted a GFP cassette in frame,
resulting in a fusion protein that contained the first 31 amino acids
of TAU. None of these two strains revealed any obvious impair-
ment [at the time, the Tucker strain was only used as a “tool” to
study neurotrophins; we have, however, since used this strain for
behavioral studies (Ittner et al., 2010)]. Interestingly, in the Daw-
son strain, MAP1A levels were increased twofold at birth, while
they were reduced back to normal levels as the mice became older
suggesting that MAP1A may compensate for the loss of TAU dur-
ing early brain development, but not in the mature brain (Dawson
et al., 2001). In keeping with the very first in vitro studies (Caceres
and Kosik, 1990), primary neurons obtained from this knock-out
strain showed a slowed maturation with reduced neurite length
throughout all developmental stages and a reduced axon length
of stage 3 (onset of polarity) neurons (Dawson et al., 2001). A
fourth TAU knockout was established in 2007, again by inserting
a selection cassette into exon 1, but the cassette was flanked by
FRT (flippase recognition target) recombination motifs to allow
for subsequent manipulation of the targeted MAPT gene (Fujio
et al., 2007). Not surprisingly, the mice looked quite normal, and
MAP1A levels were found to be increased as previously reported
in two of the three knock-out strains. Taken together, TAU is not
essential in mice, although small differences were found between
the four strains with regards to compensatory mechanisms and
when analyzed ex vivo.
How do TAU knock-out mice fare in behavioral and motor
studies? All four strains presented with no overt phenotype up to
8 months of age (Harada et al., 1994; Dawson et al., 2001; Fujio
et al., 2007; Roberson et al., 2007; Ittner et al., 2010; Lei et al.,
2012). At 10–12 months, the Dawson mice performed like wild-
type in the radial arm and the Morris water maze (Dawson et al.,
2010). Subtle motor deficits were detected at 3–3.5 months when
the knock-out mice showed an increased latency to cross a beam
and also made more slipped steps, but otherwise showed normal
motor functions (Morris et al., 2011a). However, at 12 months
of age, the Harada mice displayed signs of muscle weakness in
the wire-hanging test, reduced balance in the rod-walking test,
hyperactivity in a novel environment and impaired contextual fear
conditioning (Ikegami et al., 2000). Interestingly, muscle weakness
was also evident in heterozygous knock-out mice. Spatial learning,
however, of this TAU knock-out strain was normal, when assessed
in the eight-arm radial and the Morris water maze (Ikegami et al.,
2000). The most pronounced phenotype was recently reported in
the Dawson strain kept on a C57BL/6/SV129 background, with
Parkinsonism evident at 12 months of age due to a massive loss
of dopaminergic neurons in the SNpc, associated with motor
impairments such as a reduced performance on the Rotarod and
decreased locomotion in the open field (Lei et al., 2012). Because
these findings contradict the earlier studies, Morris et al. (2013)
performed a detailed behavioral and motor analysis of the Daw-
son strain that was kept on a C57BL/6 background. They found
in their mice that the chronic lack of TAU did not impair learning
and memory functions in the Morris water maze and the novel
object recognition test, neither at 11–17 nor at 21–22 months of
age (Morris et al., 2013). Interestingly, at 12–15 months the knock-
out mice weighed more (with 21–22 month-old mice showing a
trend) (Morris et al., 2013), while K369I TAU over-expressing mice
weigh less (Ittner et al., 2008). The knockout did not alter rearing
or activity in the open field, however, both aging and TAU ablation
reduced the latency to fall off the Rotarod and this was corre-
lated with body weight. At 12–15 months, TAU knock-out mice
took longer to descend from the pole than heterozygous knock-
out or wild-type mice, whereas for the older age group latencies
did not differ. Together this suggests that complete TAU ablation
causes subtle motor deficits that are related to an increased body
weight. Finally, the newer study did find up to 16% reductions in
dopamine levels but this was not sufficient to cause Parkinsonism
nor did the administration of l-DOPA improve the performance
of the mice in the pole test (Morris et al., 2013). In contrast to
the work by Lei et al. (2012), no iron accumulation was found
in brain areas such as the hippocampus, striatum or SN. A rea-
son for these discrepancies may be the difference in the genetic
background (C57BL/6/SV129 versus C57BL/6) as this has been
reported to affect brain metal levels in both transgenic and normal
mice (Maynard et al., 2006).
It is apparent that differences in genetic background and design
of the targeting construct have an impact on the phenotype of
transgenic animals. Another confounding factor for the study of
TAU is the presence of other MAPs, which appear to share sev-
eral biological roles (Dehmelt and Halpain, 2005; Sontag et al.,
2012). Potential compensatory functions attributable to closely
related MAPs can be excluded in the nematode C. elegans, where
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protein with TAU-like repeats (PTL-1) is the sole homolog of
TAU/MAP2/MAP4 in the worm (McDermott et al., 1996; Gor-
don et al., 2008), meaning that shared physiological functions of
the different family members can be addressed.
PTL-1 contains a high level of sequence homology to
TAU/MAP2/MAP4 within the microtubule-binding repeat (MBR)
domain in the carboxy-terminus. Analysis of aptl-1 transcriptional
reporter line demonstrates that PTL-1 has a neuronal expression
pattern in adult worms, and in addition PTL-1 has been shown
to regulate microtubule assembly in vitro (Goedert et al., 1996;
McDermott et al., 1996). PTL-1 has been implicated in the reg-
ulation of microtubule-based motility in several neurons (Tien
et al., 2011) and in the response to gentle touch (Gordon et al.,
2008). Aging-related damage in C. elegans neurons is evident
by neurons displaying abnormal structures such as branching
or blebbing from the cell body or axon (Figure 1), and these
changes progressively accumulate as the worms age (Pan et al.,
2011; Tank et al., 2011; Toth et al., 2012). Using two ptl-1 mutant
strains, one a null knockout (Gordon et al., 2008) and the other
putatively generating a protein product containing only the N-
terminal region [i.e., similar to our ∆Tau truncation construct
(Ittner et al., 2010)], it was observed that ptl-1 mutant strains
showed an increased incidence of abnormal structures compared
with wild-type animals (Chew et al., 2013). This suggests that
the neurons of ptl-1 mutant animals develop signs of aging at a
faster rate than in wild-type animals. In addition,ptl-1mutant ani-
mals are also short-lived compared with wild-type controls (Chew
et al., 2013). These phenotypes of accelerated neuronal aging and
shortened organismal lifespan were rescued by re-expressing PTL-
1 in a ptl-1 null mutant. Interestingly, increasing the number
of gene copies of ptl-1 by incorporating the ptl-1 transgene in
a wild-type background was observed to mirror both the neu-
ronal and lifespan phenotypes observed in the ptl-1mutant strains,
indicating that gene dosage of PTL-1 is vital. This demonstrates
a key role of PTL-1 in maintaining neuronal health with age
and in regulating whole organism lifespan (Chew et al., 2013).
These findings in C. elegans show that levels of PTL-1 need to
be tightly regulated, suggesting that therapeutic strategies involv-
ing the reduction of TAU levels should not lead to a complete
reduction of TAU.
CONCLUDING REMARKS
What causes sporadic forms of AD is not known, but it is tempting
to speculate that Aβ and TAU act through a combination of exci-
totoxicity, inhibition of axonal transport and aberrant localization
as well as combined effects on mitochondria. It is at the synapse
where Aβ induces damage and impairs memory-related electro-
physiological properties (Masliah, 1995; Arendt, 2009; Wu et al.,
2010). Under basal conditions, mild activation of the NMDAR
results in physiological ROS production, while under neurodegen-
erative conditions, triggered by Aβ, over-activation of NMDARs
causes excessive calcium influx and generates NO (Nakamura and
Lipton, 2011). These changes in calcium can affect mitochondria
(Stanika et al., 2012). Furthermore, axonal transport of cargoes
including mitochondria is impaired when TAU detaches from the
microtubules and localizes to the somatodendritic domain (Ishi-
hara et al., 1999; Ittner et al., 2008). It has been proposed that
in disease conditions such as AD, rare species of toxic TAU exist
that need to be removed in order to restore neuronal functions.
Other possibilities include a role for non-coding RNAs including
mi-RNAs and truncated forms of TAU in toxicity, as discussed
elsewhere (Schonrock et al., 2010; Hebert et al., 2012; Zilka et al.,
FIGURE 1 | Neuronal aging in C. elegans is demonstrated by the
accumulation of abnormal neuronal structures. Reporter lines expressing
GFP in particular neuronal subsets are used to track these phenotypes as
animals age. In touch receptor neurons (top), branching from the cell body or
axon, as well as beading along the axon, can be observed. In GABAergic
motor neurons (bottom), branching from commissures extending dorsally can
be visualized. These phenotypes usually accumulate in late adulthood in
wild-type animals, but in ptl-1 mutant strains these structures can be seen
starting in early to mid-adulthood. Arrows indicate branching, asterisks
indicate beading. Scale bar = 50µ. Ventral is down.
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2012). As discussed here, simply reducing TAU levels may be ther-
apeutically beneficial. Work in TAU knock-out mice and PTL-1
knock-out worms suggests that especially in an aging brain, one
would not aim for a full ablation of TAU expression. This is also
because the TAU/FYN interaction is required for oligodendrocyte
functions including myelination. Expression of the N-terminal
domain of TAU (a construct similar to∆Tau) alone causes abnor-
mal sorting of FYN, poor myelination and seizures (Klein et al.,
2002). However, if one were to succeed in reducing TAU lev-
els by any form of therapeutic intervention, in practical terms
it is unlikely that this reduction will be complete. For a posi-
tive therapeutic outcome, it might even be sufficient to reduce
TAU expression after a pathology has developed as suggested by
studies in mice with inducible TAU expression, including those
that express shorter variants of TAU (Van der Jeugd et al., 2012;
Hochgrafe et al., 2013).
From a therapeutic point of view, besides manipulating TAU
levels, its localization and the interaction with other proteins,
a range of alternative strategies can be pursued. One is restor-
ing neuronal functions by transplanting stem cells to provide
neurotropic support (Yamasaki et al., 2007). As far as TAU is
concerned, evidence is accumulating that its phosphorylation is
critical for TAU to be toxic, and that reducing TAU phosphory-
lation is a promising strategy (Gong and Iqbal, 2008). What is
not entirely clear is whether this requires distinct phosphorylation
events or whether a generally elevated level of phosphorylation is
sufficient. The latter possibility is suggested by work in Drosophila
(Steinhilb et al., 2007). In principal, one would either like to
inhibit TAU kinases such as GSK3 (Engel et al., 2006), or acti-
vate TAU phosphatases such as PP2A (Delobel et al., 2002), or
both. In fact, the PP2A activator sodium selenate that dramat-
ically reduced TAU pathology in several mouse models (van
Eersel et al., 2010) is currently evaluated in a phase IIa clinical
trial in mild to moderate AD (https://www.anzctr.org.au/Trial/
Registration/TrialReview.aspx?id=83952).
Other suitable therapeutic strategies are the restoration of mito-
chondrial function, blocking the interaction of TAU with FYN
or JIP1, or disrupting the excitotoxic complex of NMDAR and
PSD-95. Other strategies are the activation of chaperones (Ward
et al., 2012) and the use of aggregation blockers (Akoury et al.,
2013). While it is clear that Aβ plays a key role in the pathogen-
esis of AD, it is becoming even clearer that there is a future of
therapeutics for AD beyond amyloid (Lane et al., 2012; Yoshiyama
et al., 2012). Whether in practical terms it will be necessary for
the efficacy of emerging therapeutic strategies to exactly deter-
mine which TAU species is the most toxic form, remains to be
determined.
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